Dynamic Technology Lab Private Ltd Purchases Shares of 22,982 Solid Biosciences Inc. $SLDB

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Solid Biosciences Inc. (NASDAQ:SLDB) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 22,982 shares of the company’s stock, valued at approximately $112,000.

A number of other institutional investors have also recently made changes to their positions in SLDB. CWM LLC lifted its position in shares of Solid Biosciences by 15,188.5% in the first quarter. CWM LLC now owns 7,950 shares of the company’s stock worth $29,000 after buying an additional 7,898 shares in the last quarter. Allianz Asset Management GmbH purchased a new position in Solid Biosciences during the 1st quarter valued at approximately $100,000. XTX Topco Ltd bought a new stake in Solid Biosciences in the 1st quarter worth approximately $151,000. Sfmg LLC purchased a new stake in shares of Solid Biosciences during the 1st quarter worth approximately $93,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Solid Biosciences by 8.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,607 shares of the company’s stock valued at $254,000 after acquiring an additional 5,220 shares during the last quarter. Hedge funds and other institutional investors own 81.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Solid Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, October 19th. JPMorgan Chase & Co. dropped their price objective on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Citigroup decreased their target price on shares of Solid Biosciences from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, Barclays set a $9.00 price target on Solid Biosciences and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.70.

Solid Biosciences Trading Up 4.1%

Shares of SLDB opened at $5.36 on Friday. The company’s fifty day simple moving average is $5.36 and its 200-day simple moving average is $5.17. The company has a market cap of $417.60 million, a P/E ratio of -2.15 and a beta of 2.75. Solid Biosciences Inc. has a twelve month low of $2.41 and a twelve month high of $7.37.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). Analysts predict that Solid Biosciences Inc. will post -2.84 earnings per share for the current fiscal year.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.